CHERISSE PERU: Open Payments
NPI 1417598020 · LANSING, MI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$666 in 29 payments from 13 companies in 2025. Trend: 2023 $455 · 2024 $784 · 2025 $666
Food & beverage: $666
| Company | Payments | Amount |
|---|---|---|
| Calliditas Therapeutics US Inc. | 4 | $135 |
| Novartis Pharmaceuticals Corporation | 4 | $115 |
| Travere Therapeutics, Inc. | 5 | $106 |
| Amgen Inc. | 4 | $73 |
| Novo Nordisk Inc | 2 | $56 |
| Mallinckrodt Hospital Products Inc. | 2 | $52 |
| Lilly USA, LLC | 2 | $29 |
| Alnylam Pharmaceuticals Inc. | 1 | $19 |
| Ardelyx, Inc. | 1 | $18 |
| AKEBIA THERAPEUTICS INC | 1 | $17 |
Products named: TARPEYO, Fabhalta, Vanrafia, TAVNEOS, TERLIVAZ, Rybelsus, JARDIANCE, Ozempic.
Industry payments across MI — which companies pay providers there.
